
|Videos|December 2, 2022
Advent of Bispecific Antibodies for Relapsed/Refractory Follicular Lymphoma
Author(s)Matthew J. Matasar, MD, Laurie Sehn, MD
Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma
4
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
5





















